Glycomimetics Inc (GLYC) SEC Filing 10-Q Quarterly Report for the period ending Wednesday, June 30, 2021

Glycomimetics Inc

CIK: 1253689 Ticker: GLYC





Completion of enrollment is expected by year-end 2021 for the Company-sponsored Phase 3 pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML)
Completion of enrollment is expected by year-end 2021 for the Phase 2 portion of the NCI-sponsored Phase 2/3 registration trial evaluating uproleselan in newly diagnosed AML patients fit for chemotherapy
During the quarter and shortly after the quarter close, GlycoMimetics announced the initiation of three investigator-sponsored trials (ISTs) to expand the scope of its clinical research with uproleselan in AML and multiple myeloma
Yesterday, the Company announced that Harout Semerjian will become chief executive officer, effective August 6, to succeed Rachel King, who is retiring
Hosting a conference call and webcast today at 8:30 a.m. ET

ROCKVILLE, MD, August 5, 2021--

 GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended June 30, 2021 and highlighted recent events. Cash and cash equivalents at June 30, 2021 were $118.9 million.

“There are now six trials underway evaluating our lead clinical candidate, uproleselan, including three registration trials and three ISTs, which we anticipate will provide clinical data flow beginning in 2022. Importantly, recruitment rates in both our Company-sponsored Phase 3 trial and the National Cancer Institute’s Phase 2 portion of the Phase 2/3 trial support our expectation that enrollment in both studies can be completed by the end of this year. The support of clinicians who are enrolling patients in our global studies, and now the new ISTs, has made it possible to broaden the scope of our uproleselan clinical research to address unmet needs in AML and beyond,” commented  Chief Executive Officer Rachel King.

Operational Highlights


Enrollment of GlycoMimetics’ pivotal Phase 3 trial in relapsed/refractory AML continued in the U.S., Canada, Australia and Europe at a steady pace throughout the second quarter of 2021. The Company continues to project that enrollment will be completed by year-end 2021.

The following information was filed by Glycomimetics Inc (GLYC) on Thursday, August 5, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Glycomimetics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Glycomimetics Inc.


Assess how Glycomimetics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Cash Flow
Inside Glycomimetics Inc's 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Balance Sheets
Balance Sheets (Parenthetical)
Statements Of Cash Flows
Statements Of Operations And Comprehensive Loss
Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Summary Of Accrued Expenses (Details)
Description Of The Business
Income Taxes
Income Taxes (Details)
Leases (Details)
Leases (Tables)
Leases - Components Of Lease Expense (Details)
Leases - Maturities Of Lease Liability (Details)
License And Collaboration Agreements
License And Collaboration Agreements - Additional Information (Details)
Prepaid Expenses And Other Current Assets
Prepaid Expenses And Other Current Assets (Tables)
Prepaid Expenses And Other Current Assets - Summary Of Prepaid Expenses And Other Current Assets (Details)
Property And Equipment
Property And Equipment (Details)
Property And Equipment (Tables)
Risks And Uncertainties
Significant Accounting Policies
Significant Accounting Policies (Tables)
Significant Accounting Policies - Fair Value Measurements (Details)
Significant Accounting Policies - Net Loss Per Common Share (Details)
Significant Accounting Policies - Stock-Based Compensation (Details)
Stockholders Equity (Tables)
Stockholders' Equity
Stockholders' Equity - Company's Stock Option Activity (Details)
Stockholders' Equity - Equity Offerings (Details)
Stockholders' Equity - Incentive Plans (Details)
Stockholders' Equity - Inducement Plan (Details)
Stockholders' Equity - Inducement Plan - Stock Option Activity (Details)
Stockholders' Equity - Stock-Based Compensation Expense (Details)
Stockholders' Equity - Summary Of Rsu Activity (Details)
Stockholders' Equity - Weighted-Average Assumptions (Details)
Summary Of Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Glycomimetics Inc provided additional information to their SEC Filing as exhibits

Ticker: GLYC
CIK: 1253689
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-21-010410
Submitted to the SEC: Thu Aug 05 2021 8:16:22 AM EST
Accepted by the SEC: Thu Aug 05 2021
Period: Wednesday, June 30, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: